Table 5.
Exposure to Study Treatment and Nutrient Intake: Intention-to-Treat Population, With No Significant Group Differences
| At Study Start (Day 1) |
Main Study Phasea |
Complete Study Phaseb |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Test Group (SMOFlipid) | n | Control Group | n | Test Group (SMOFlipid) | n | Control Group | n | Test Group (SMOFlipid) | n | Control Group | |
| Daily parenteral glucose intake, g/kg BW/d | 26 | 14.3 (3.0) | 27 | 15.3 (1.5) | 26 | 12.5 (3.1) | 27 | 13.2 (1.7) | 26 | 12.2 (2.8) | 27 | 12.6 (1.5) |
| Daily parenteral amino acid intake, g/kg BW/d | 26 | 2.5 (0.5) | 27 | 2.7 (0.3) | 26 | 2.2 (0.5) | 27 | 2.3 (0.3) | 26 | 2.2 (0.5) | 27 | 2.2 (0.3) |
| Daily parenteral fat intake, g/kg BW/d | 26 | 1.0 (0.2) | 27 | 1.0 (0.2) | 26 | 2.0 (0.4) | 27 | 2.0 (0.4) | 26 | 2.1 (0.5) | 27 | 2.1 (0.5) |
| Daily enteral fat intake, g/kg BW/d | 23 | 0.42 (0.37) | 24 | 0.31 (0.20) | 24 | 0.76 (0.41) | 26 | 0.70 (0.41) | 24 | 0.82 (0.36) | 27 | 0.77 (0.36) |
| Daily parenteral + enteral fat intake, g/kg BW/d | 26 | 1.42 (0.47) | 27 | 1.32 (0.24) | 26 | 2.69 (0.48) | 27 | 2.61 (0.68) | 26 | 2.87 (0.42) | 27 | 2.87 (0.62) |
| Daily enteral/total fat intake ratio | 23 | 0.25 (0.15) | 24 | 0.21 (0.11) | 24 | 0.27 (0.15) | 26 | 0.24 (0.11) | 24 | 0.28 (0.14) | 27 | 0.25 (0.10) |
Values presented as mean (SD). BW, body weight.
a
Defined as the period from the day of inclusion until completion of treatment day 7.
b
Defined as the period from the day of inclusion until termination of study treatment application.